Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
2.685
-0.015 (-0.56%)
At close: Mar 9, 2026, 4:00 PM EDT
2.740
+0.055 (2.05%)
After-hours: Mar 9, 2026, 4:00 PM EDT
Lantern Pharma Employees
Lantern Pharma had 24 employees as of December 31, 2024. The number of employees increased by 3 or 14.29% compared to the previous year.
Employees
24
Change (1Y)
3
Growth (1Y)
14.29%
Revenue / Employee
n/a
Profits / Employee
-$788,351
Market Cap
30.03M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Kyntra Bio | 225 |
| Pluri | 142 |
| Werewolf Therapeutics | 39 |
| Tempest Therapeutics | 21 |
| NeuroSense Therapeutics | 17 |
| FibroBiologics | 15 |
| Rein Therapeutics | 11 |
| RenovoRx | 10 |
LTRN News
- 27 days ago - Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026 - Business Wire
- 6 weeks ago - Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas - Business Wire
- 2 months ago - Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies - Business Wire
- 3 months ago - Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials - Business Wire
- 3 months ago - Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript - Seeking Alpha
- 4 months ago - Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 4 months ago - Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET - Business Wire